Characteristics | DM | P | No-DM | P | ||
---|---|---|---|---|---|---|
G2‑DES N = 1862 | BP‑DES N = 421 | G2‑DES N = 4232 | BP‑DES N = 1151 | |||
Age (years) | 59.0 ± 9.7 | 59.7 ± 9.7 | 0.814 | 57.5 ± 10.6 | 58.5 ± 10.4 | 0.241 |
Sex (male) | 1411 (75.8) | 314 (74.6) | 0.607 | 3307 (78.1) | 872 (75.8) | 0.085 |
BMI (kg/m2) | 26.3 ± 3.1 | 26.2 ± 3.1 | 0.595 | 25.8 ± 3.2 | 25.8 ± 3.1 | 0.754 |
LVEF (%) | 62.7 ± 7.5 | 61.8 ± 7.9 | 0.207 | 63.1 ± 7.2 | 61.8 ± 7.9 | 0.262 |
Hypertension (n, %) | 1284 (69.0) | 314 (74.6) | 0.023 | 2545 (60.1) | 726 (63.1) | 0.070 |
Hyperlipidemia (n, %) | 1383 (74.3) | 306 (72.7) | 0.502 | 2754 (65.1) | 717 (62.3) | 0.080 |
Current smoker (n, %) | 1014 (54.5) | 240 (57.0) | 0.342 | 2414 (57.0) | 685 (59.5) | 0.132 |
Family history (n, %) | 486 (26.1) | 102 (24.2) | 0.427 | 1047 (24.7) | 264 (22.9) | 0.206 |
Stroke history (n, %) | 231 (12.4) | 60 (14.3) | 0.305 | 369 (8.7) | 118 (10.3) | 0.108 |
PAD (n, %) | 62 (3.3) | 19 (4.5) | 0.236 | 99 (2.3) | 18 (1.6) | 0.110 |
COPD (n, %) | 43 (2.3) | 10 (2.4) | 0.935 | 98 (2.3) | 26 (2.3) | 0.158 |
OMI (n, %) | 348 (18.7) | 101 (24.0) | 0.013 | 749 (17.7) | 211 (18.3) | 0.619 |
Previous PCI (n, %) | 480 (25.8) | 133 (31.6) | 0.015 | 976 (23.1) | 247 (21.5) | 0.250 |
Previous CABG (n, %) | 82 (4.4) | 21 (5.0) | 0.602 | 163 (3.9) | 25 (2.2) | 0.006 |
Serum creatinine (ml/min) | 74.9 ± 16.7 | 76.9 ± 17.8 | 0.233 | 75.4 ± 15.3 | 76.2 ± 15.5 | 0.425 |
HbA1c (%) | 7.8 ± 1.4 | 7.9 ± 1.4 | 0.772 | 6.1 ± 0.6 | 6.1 ± 0.6 | 0.744 |
Clinical presentation (n, %) | ||||||
 Stable angia | 796 (42.7) | 175 (41.6) | 0.658 | 1631 (38.5) | 432 (37.5) | 0.533 |
 NSTE-ACS | 857 (46.0) | 189 (44.9) | 0.674 | 2026 (47.9) | 534 (46.4) | 0.373 |
 STEMI | 209 (11.2) | 57 (13.5) | 0.181 | 574 (13.6) | 185 (16.1) | 0.030 |
Medication (cases, %) | ||||||
 Aspirin | 1841 (98.9) | 419 (99.5) | 0.289 | 4173 (98.6) | 1140 (99.0) | 0.244 |
 Clopidogrel | 1840 (98.8) | 416 (98.8) | > 0.999 | 4159 (98.3) | 1138 (98.9) | 0.153 |
 DAPT | 1821 (97.8) | 415 (98.6) | 0.311 | 4104 (97.0) | 1131 (98.3) | 0.018 |
 GP IIIb/IIa inhibitors | 206 (11.1) | 62 (14.7) | 0.035 | 500 (11.8) | 217 (18.9) | < 0.001 |
 Statin | 1774 (95.3) | 406 (96.4) | 0.299 | 4071 (96.2) | 1104 (95.9) | 0.663 |
 β‑blocker | 1705 (91.6) | 403 (95.7) | 0.004 | 3782 (89.4) | 1021 (88.7) | 0.521 |
 Calcium antagonist | 956 (51.3) | 221 (52.5) | 0.669 | 2002 (47.3) | 518 (45.0) | 0.165 |
 Nitrate | 1807 (97.0) | 414 (98.3) | 0.141 | 4130 (97.6) | 1127 (97.9) | 0.518 |
 PPI | 341 (18.3) | 79 (18.8) | 0.829 | 836 (19.8) | 266 (23.1) | 0.012 |
Therapeutic status for DM (n, %) | ||||||
 Diet and exercise | 342 (18.4) | 76 (18.1) | 0.880 | – | – | – |
 Antidiabetic agents | 836 (44.9) | 209 (49.6) | 0.078 | – | – | – |
 Insulin | 494 (26.5) | 104 (24.7) | 0.441 | – | – | – |
 Insulin and antidiabetic agents | 190 (10.2) | 32 (7.6) | 0.104 | – | – | – |